757 / 1708
Dose Reduction in Low-Risk Rhabdomyosarcoma
•
Children’s Oncology Group D9602 Study
•
Eligibility:
1. nonmetastatic rhabdomyosarcoma in a favorable site
(orbit, non-parameningeal head and neck,
nonprostate/nonbladder genitourinary, biliary tract)
2. nonmetastatic rhabdomyosarcoma in an unfavorable
site with gross total resection of all tumor at diagnosis
(Group I or II)
3. initially alveolar subtype included (1997) but
later excluded (1999)
Breneman J et al. Int J Radiat Oncol Biol Phys 2012; 83:720-6